The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
The Main campaign started from October 2
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Subscribe To Our Newsletter & Stay Updated
